Decoy Therapeutics Inc. (DCOY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.745x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Decoy Therapeutics Inc. (DCOY) liquidity interval to measure how many days the company can operate on defensive assets alone.
Decoy Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ROLLING OPTICS HOLDING AB
F:5LN
|
-0.033x |
|
Essentra PLC
LSE:ESNT
|
0.024x |
|
Damon Inc. Common Stock
NASDAQ:DMN
|
0.392x |
|
Copper Lake Resources Ltd
V:CPL
|
-0.058x |
|
Renegade Exploration Ltd
AU:RNX
|
-0.170x |
|
NetJobs Group AB
ST:NJOB
|
-0.675x |
|
Central Asia Metals Plc
LSE:CAML
|
0.048x |
|
S&U plc
LSE:SUS
|
-0.193x |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Decoy Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.89 Million | $-4.83 Million | -0.820x | +72.62% |
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more